🇺🇸 FDA
Pipeline program

METHYLPREDNISOLONE, Placebo of CRESEMBA, CRESEMBA 200 mg powder for concentrate for solution for infusion, Placebo of methylprednisolone

APHP180584

Phase 3 small_molecule active

Quick answer

METHYLPREDNISOLONE, Placebo of CRESEMBA, CRESEMBA 200 mg powder for concentrate for solution for infusion, Placebo of methylprednisolone for patients with acute respiratory failure from undetermined etiology is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
patients with acute respiratory failure from undetermined etiology
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials